6-hexyl-7-hydroxy-3-(7-methylimidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 6-hexyl-7-hydroxy-3-(7-methylimidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one
• 英文别名: 6-hexyl-7-hydroxy-3-(7-methylimidazo[1,2-a]pyridin-2-yl)chromen-2-one
• 化学式: C₂₃H₂₄N₂O₃
• 分子量: 376.4
• InChiKey: HWQBVLBLCGPFTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA DYSTROPHIE MYOTONIQUE DE TYPE 1
  申请人：UNIV SOUTHERN CALIFORNIA

  公开号：WO2014028025A1

  公开（公告）日：2014-02-20

  Disclosed is a compound for treatment of Myotonic Dystrophy type 1 having the formula (I) wherein X is selected from the group consisting of O, N, C, or S, Y is a homo- or heteroatomic 5-membered ring comprising one or more atoms selected from the group consisting of N, O, S, and C, Z is an optionally substituted aryl group or optionally substituted heteroaryl, including but not limited to halogenated benzenes, pyridines, substituted benzene, substituted pyridine, R2 = hydroxy, acyl, alkoxyl, esters, ethers, cyclic ethers, and lactones, R3 = H, alkyl, an optionally substituted alkyl, aliphatic ether, ester, cyclic unsaturated and aromatic ring groups, and R1, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, and alkoxyl or a pharmaceutically or cosmetically acceptable salt, solvate, or hydrate thereof.

  揭示了一种用于治疗肌萎缩性肌病类型1的化合物，其化学式为(I)，其中X选自O、N、C或S组成的群，Y是一个包括来自N、O、S和C组成的一个或多个原子的同核或异核5元环，Z是一个可选择取代的芳基团或可选择取代的杂环烃基，包括但不限于卤代苯、吡啶、取代苯、取代吡啶，R2 = 羟基、酰基、烷氧基、酯、醚、环醚和内酯，R3 = H、烷基、可选择取代的烷基、脂肪醚、酯、环烯烃和芳香环基，而R1、R4和R5独立地选自氢、卤素、烷基和烷氧基或其药学上或化妆上可接受的盐、溶剂化合物或水合物。
• Compositions and Methods for Treating Myotonic Dystrophy Type 1
  申请人：REDDY Sita

  公开号：US20140051709A1

  公开（公告）日：2014-02-20

  Disclosed is a compound for treatment of Myotonic Dystrophy type 1 having the formula: Wherein X is selected from the group consisting of O, N, C, or S, Y is a homo- or heteroatomic 5-membered ring comprising one or more atoms selected from the group consisting of N, O, S, and C, Z is an optionally substituted aryl group or optionally substituted heteroaryl, including but not limited to halogenated benzenes, pyridines, substituted benzene, substituted pyridine, R 2 =hydroxy, acyl, alkoxyl, esters, ethers, cyclic ethers, and lactones, R 3 =H, alkyl, an optionally substituted alkyl, aliphatic ether, ester, cyclic unsaturated and aromatic ring groups, and R 1 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, alkyl, and alkoxyl or a pharmaceutically or cosmetically acceptable salt, solvate, or hydrate thereof.

  揭示了一种用于治疗肌萎缩性肌病型1的化合物，其化学式为：其中X选自O、N、C或S组成的群，Y是一个由N、O、S和C组成的原子选自的同源或异源5-成员环，Z是一个可选择取代的芳基或可选择取代的杂环烃基，包括但不限于卤代苯、吡啶、取代苯、取代吡啶，R2=羟基、酰基、烷氧基、酯、醚、环醚和内酯，R3=H、烷基、一个可选择取代的烷基、脂肪醚、酯、环状不饱和和芳香环基，R1、R4和R5独立选自氢、卤素、烷基和烷氧基或其药学上或化妆品上可接受的盐、溶剂合物或水合物。
• Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
  申请人：Menta Ernesto

  公开号：US20060122387A1

  公开（公告）日：2006-06-08

  The compounds of formula (I) wherein A and R1-R5 are as defined in the description, are inhibitors of Vascular Endothelial Growth Factor and are useful as angiogenesis inhibitors and antiproliferative agents.

  式(I)中的化合物，其中A和R1-R5如描述中所定义，是血管内皮生长因子的抑制剂，可用作抗血管生成剂和抗增殖剂。
• Methods and compositions for inhibiting mutant EGFR signaling
  申请人：The Governing Council of the University of Toronto

  公开号：US11123330B2

  公开（公告）日：2021-09-21

  Methods of inhibiting mutant EGFR and methods of treating a subject afflicted with a lung cancer having a mutant EGFR, having for example a C797 mutation, are described. The methods comprise administering to a cell or a subject in need thereof a therapeutically effective amount of a compound selected from 3-(1,3-benzoxazol-2-yl)-7-(diethylamino)-2H-chromen-2-one and a structurally related analog thereof; midostaurin; and AZD7622 and a structurally related analog thereof; and mixtures thereof. Compositions and combinations comprising the compounds of the disclosure as well as uses are also provided.

  本发明描述了抑制突变表皮生长因子受体的方法和治疗具有突变表皮生长因子受体（例如具有C797突变）的肺癌患者的方法。这些方法包括向细胞或有需要的受试者施用治疗有效量的选自3-(1,3-苯并恶唑-2-基)-7-(二乙氨基)-2H-色烯-2-酮及其结构相关类似物、米多司他林、AZD7622及其结构相关类似物和它们的混合物的化合物。还提供了包含本公开化合物的组合物和组合物以及用途。